The global non-small cell lung cancer market is on track for exceptional growth, driven by increasing demand for innovative treatment solutions. According to recent market projections, the market ...

The global non-small cell lung carcinoma market is poised for significant expansion over the next decade, according to new industry projections. Valued at USD 8.25 billion in 2023, the NSCLC market is ...

Explore the evolving landscape of non-small cell lung cancer (NSCLC) treatment, where targeted therapies address ten actionable genomic alterations (AGAs). Discover innovations in EGFR mutations, ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

The HER2-targeted therapy zongertinib demonstrated clinical benefits for previously treated patients with advanced ...

Roche has claimed a breakthrough designation from the FDA for a cancer test that combines an antibody assay with ...

The Small Cell Lung Cancer market report also offers comprehensive insights into the Small Cell Lung Cancer market size, ...

The investigational oral tyrosine kinase inhibitor (TKI) zongertinib showed promise in patients with previously treated HER2 ...

Novocure (NASDAQ: NVCR) announced today that Optune Lua® has received a CE (Conformité Européenne) Mark for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) ...

Zongertinib, a HER2-targeted therapy made by Boehringer Ingelheim, demonstrated promising results in HER2-mutant lung cancer.

A subset of patients with non-small cell lung cancer (NSCLC) who discontinued immune checkpoint inhibitor (ICI) therapy due ...